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Clinical Management Guideline for hypertension 
Clinical parameters If Age<55 If Age≥55 Messages 
if (SBP≥140<160) OR 
(DBP≥90<100) 
Life Style Advices, If on 
medication, continue 
Life Style Advices, If on 
medication, continue 
if ((SBP≥160) OR 






FAILURE, PVD, HEART 
BLOCK, DIABETES) 
1st: ACEi/ARB or CCB 
2nd: ACEi/ARB + CCB or 
ACEi/ARB+Diuretic 
3rd: ACEi/ARB + CCB + Diuretic 
1st: CCB or Diuretics 
2nd: ACEi/ARB + CCB or CCB + 
Diuretic 
3rd: ACEi/ARB + CCB + Diuretic 
If on medication, consider increasing 
the dose up or adding 2nd/3rd line 
drug. 




2nd: CCB + ACEi/ARB  or CCB + 
Diuretic 
3rd: ACEi/ARB + CCB + Diuretic 
1st: CCB 
2nd: CCB + ACEi/ARB  or CCB 
+ Diuretic 
3rd:ACEi/ARB + CCB + Diuretic 
Avoid BB. If on medication, consider 
increasing the dose up or adding 
2nd/3rd line drug. 
if ((SBP≥140) OR (DBP 
≥90)) AND (DIABETES) 
1st: ACEI/ARB + ASA 
2nd: ACEi/ARB + CCB or 
ACEi/ARB + Diuretic along with 
ASA 
3rd: ACEi/ARB + CCB + Diuretic 
along with ASA 
4th: Add Alpha Blocker or BB 
along with ASA 
1st: CCB (PREFERRED) or ASA 
OR ACEi/ARB along with ASA 
2nd: ACEi/ARB + CCB or 
ACEi/ARB + Diuretic  along with 
ASA 
3rd: ACEi/ARB + CCB + Diuretic 
along with ASA 
4th: Add Alpha Blocker or BB 
along with ASA 
If on medication, consider titrating 
the dose up or adding 2nd/3rd line 
drug. ASA Contraindicated if 
SBP>160 or DBP>100 or having 
gastritis or Aspirin Allergy 




1st: BB + ASA 
2nd: BB + CCB or BB + 
ACEi/ARB along with ASA 
3rd: BB + ACEi/ARB + 
CCB/Diuretics along with ASA 
1st: BB + ASA 
2nd: BB + CCB or BB + 
ACEi/ARB along with ASA 
3rd: BB + ACEi/ARB + 
CCB/Diuretics along with ASA 
If on medication, consider titrating 
the dose up or adding 2nd/3rd line 
drug. ASA Contraindicated if 
SBP>160 or DBP>100 or having 
gastritis or Aspirin Allergy 
if ((SBP≥140) OR (DBP 1st: CCB  1st: CCB  Avoid ACEi/ARB. If on medication, 
333 
 
Clinical Management Guideline for hypertension 





2nd: CCB + Diuretic 
3rd: ADD Alpha Blocker or BB or 
Other Diuretic 
2nd: CCB + Diuretic 
3rd: ADD Alpha Blocker or BB or 
Other Diuretic 
 
consider titrating the dose up or 
adding 2nd/3rd line drug. 
if ((SBP≥140) OR (DBP 
≥90)) AND ((PVD)) 
1st: CCB + ASA 
2nd: CCB + ACEi/ARB or CCB + 
Diuretic along with ASA 
3rd: CCB + ACEi/ARB + Diuretic 
along with ASA 
4th: Add Alpha Blocker or Other 
Diuretic along with ASA 
1st: CCB + ASA 
2nd: CCB + ACEi/ARB or CCB + 
Diuretic along with ASA 
3rd: CCB + ACEi/ARB + Diuretic 
along with ASA 
4th: Add Alpha Blocker or Other 
Diuretic along with ASA 
Avoid BB. If on medication, consider 
titrating the dose up or adding 
2nd/3rd line drug. ASA 
Contraindicated if SBP>160 or 
DBP>100 or having gastritis or 
Aspirin Allergy 
if ((SBP≥140) OR (DBP 
≥90)) AND ((HEART 
BLOCK)) 
1st: ACEi/ARB 
2nd: ACEi/ARB + CCB or 
ACEi/ARB + Diuretic  
3rd: ACEi/ARB + CCB + Diuretic 
4th: Add Alpha Blocker or Other 
Diuretic 
1st: CCB (PREFERRED) OR 
ACEi/ARB 
2nd:CCB + ACEi/ARB or CCB + 
Diuretic 
3rd: CCB + ACEi/ARB + Diuretic
4th: Add Alpha Blocker or Other 
Diuretic 
Verify Again. DILTIAZEM & 
VERAPAMIL & BB 
Contraindicared. If on medication, 
consider titrating the dose up or 
adding 2nd/3rd line drug. 
if DBP≥130 
Hypertensive emergency. Refer the 






Clinical Management Guideline for Diabetes Mellitus 
FAIR CONTROL, INSUFFICIENT 
CONTROL= 
((FBS<110) AND (PP=200-300)) OR ((FBS =110 - 130) AND (PP=140-300)) OR 
(((FBS>130) AND (PP<=200)) 
If (No OHA USE) AND (No INSULIN USE) 
AND BMI <= 23 1 Unit SU (5mg Glibenclamide  OR   80mg Gliclazide) 
If (No OHA USE) AND (No INSULIN USE) 
AND BMI > 23 500mg Metformin 
If (1 or 2 OHA, NOT AT MAXIMUM DOSE 
is in USE) AND (NO INSULIN USE) 
Consider 1 UNIT increment ( SU { 5mg Glibenclamide, OR 80mg Gliclazide}, OR  
500mg Metformin, OR 15mg Pioglitzone) 
If (2 OHA AT MAXIMUM DOSE IS IN 
USE) AND (NO INSULIN USE) 
ADD 3rd OHA (500mg Metformin   OR   SU{ 5mg Glibenclamide,   OR   80mg 
Gliclazide}    OR    15mg Pioglitazone) 
If (3 OHA AT MAXIMUM DOSE IS IN 
USE) AND (NO INSULIN USE) Start Insulin-Bedtime NPH Dose (10 units or 0.2U/kg/day). MESSAGE* 
POOR CONTROL, VERY POOR 
CONTROL= ((FBS>130) AND (PP=201-300))  OR ((FBS<110) AND (PP≥301))  OR   ((FBS=110-130) AND (P≥301))  OR ((FBS>130) AND (PP≥301)) 
If (No OHA USE) AND (No INSULIN USE) 
AND BMI <= 23 2 Unit SU (10mg Glibenclamide  OR  160mg Gliclazide) 
If (No OHA USE) AND (No INSULIN USE) 
AND BMI > 23 1000mg Metformin 
If (1 or 2 OHA, NOT AT MAXIMUM DOSE 
is in USE) AND (NO INSULIN USE) 
Consider 2 Unit increment (2 of the same or 2 different) ( SU { 10mg Glibenclamide  OR  
160mg Gliclazide} OR 1000mg Metformin   OR   30mg Pioglitzone) 
If (2 OHA AT MAXIMUM DOSE IS IN 
USE) AND (NO INSULIN USE) 
ADD 1 Unit addition of 3rd OHA (500mg Metformin   OR   SU { 5mg Glibenclamide  
OR   80mg Gliclazide}    OR   15mg Pioglitazone) 
If (3 OHA AT MAXIMUM DOSE IS IN 
USE) AND (NO INSULIN USE) Insulin-Bedtime NPH Dose (10 units or 0.2U/kg/day).  MESSAGE* 
IF (INSULIN IN USE) AND (FBS<=70) Reduce NPH dose. MESSAGE* 
IF (INSULIN IN USE) AND (FBS>120) Increase NPH dose up to .5U/kg/day. MESSAGE* 
*MESSAGE: Review FBS after 1 week (Target FBS: 80-110).  If current insulin dose is @ .5U/kg, add AM NPH (10 units or 0.2U/kg/day), 
Maximum NPH upto 20 Units only. If target not achieved, shift to PM Insulin two times daily 
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List of Data Elements in the Smartphone-based clinical decision-support tool 
No Original List of data elements No Data elements after iterations 
1 Male/Female    1 Male/Female  
2 Age 2 Age  
3 Tobacco use (Y/N) 3 Tobacco Use (Y/N) 
4 History of diabetes (Y/N) 4 Alcohol Use (Y/N) 
5 Post-menopausal Women(Y/N) 5 Regularly exercising 
6 Family history of premature Coronary Artery 
Disease (males <55 years, female >65 years) 
(Y/N) 
6 Peripheral vascular disease (Y/N) 
7 History of heart disease (any history of heart 
attack, angina, heart failure, any surgical 
procedure on coronary vessels) (Y/N) 
7 Myocardial Infarction (Y/N) 
8 History of stroke or Transient Ischemic attack 
(Y/N) 
8 Chronic Obstructive Pulmonary 
Disease /Asthma (Y/N) 
9 History of Renal disease (renal failure - S. 
creatinine>2 mg/dl; or diabetic nephropathy) 
(Y/N) 
9 Renal/Liver Failure 
(Creatinine>3mg) (Y/N) 
10 History of vascular disease (peripheral arterial 
disease, eg, claudication; or aortic dissection) 
(Y/N) 
10 Heart Block (Y/N) 
11 History of hypertensive retinopathy (e.g. 
haemorrhages or exudates OR papilledema) 
(Y/N) 
11 Diabetes (Y/N) 
12 Any evidence of LVH (on an ECG) (Y/N) 12 Family History of Diabetes (Y/N) 
13 Any evidence of microalbuminuria / proteinuria 
and or high serum creatinine (1.2-2.0mg/dl) 
(Y/N) 
13 Waist Circumference (cm) 
14 Any evidence of atherosclerotic plaques in the 
carotids (ultrasound or radiological) (Y/N) 
14 Systolic Blood Pressure 1 
15 Any evidence of hypertensive retinopathy (Y/N) 15 Systolic Blood Pressure 2 
16 Diagnosed case of hypertension (Y/N) 16 Diastolic Blood Pressure 1 
17 If yes,  is the BP under control 17 Diastolic Blood Pressure 2 
18 Systolic Blood Pressure 1 18 Height (cm)  
19 Systolic Blood Pressure 2 19 Weight (Kg)  
20 Diastolic Blood Pressure 1 20 Fasting Blood Sugar level 
21 Diastolic Blood Pressure 2 21 Post-prandial blood sugar level 
22 Height (Mtr) 22 Oral hypoglycaemic agent use 
23 Weight (Kg) 23 Insulin Use 
24 Waist circumference (cm)    
25 Hip circumference (cm)   
26 Total Cholesterol level   
27 LDL –Cholesterol level   
28 Triglyceride level   
29 HDL-Cholesterol level   
30 Serum Creatinine level   
31 Urinary albumin (Y/N)   
32 Fasting Blood Glucose level   
33 Uric Acid (Y/N)   
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List of Data Elements in the Smartphone-based clinical decision-support tool 
No Original List of data elements No Data elements after iterations 
34 Haemoglobin level   
35 Serum Potassium level   



































Appendix – 7: Ethics approvals from the London School of Hygiene & Tropical 
Medicine, Public Health Foundation of India and Centre for Chronic Disease Control, 
New Delhi 
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